ProtonDx's core technology builds on years of innovative research on diagnostics and sample processing, fuelled by unique collaborations between engineering, medicine and molecular biology. The spinout company was founded in 2020 at Imperial College London.
The team also developed Lacewing (Digital Diagnostics platform using Lab-on-chip technology) and the Dragonfly PoC diagnostic device, which was used at the 2022 Winter Olympics and Commonwealth Games. Today, they are continuing to innovate and develop new molecular diagnostic and sample extraction technologies which can be used anywhere.
Imperial researchers working on ProtonDX
- Dr Jesus Rodriguez Manzano (Co-Founder and Chief Scientific Officer)
- Professor Pantelis Georgiou (Co-Founder and Director)
- Dr Nick Moser (Co-Founder and Chief Technology Officer)
- Dr Matthew Cavuto (Head of Engineering and Product Development)
- Dr Ivana Pennisi
The Proton DX also utilises the following assays to aid in diagnosing infections.
| Human Assays | Porcine Assays |
|---|---|
|
Skin Infection Viral Panel: Multi-pathogen test for OPV, MPOX, VZV, HSV1, and HSV2. |
Actinobacillus pleuropneumoniae (APP) |
|
Respiratory Test Panel: Multi-pathogen test for SARS-CoV-2, Flu A, Flu B, RSV, and HRV. |
Glaesserella parasuis (GPS) |
|
Malaria Species Test Panel: Multi-pathogen test for Pf, Pv, Pm, Po, and PK. |
Mycoplasma hyopneumoniae (MH) |
|
Malaria Pan/Pf Test Panel: Multi-patient test for up to 6 patients. |
Pasteurella multocida (PM) |
|
Fever Test Panel: Multi-pathogen test for DENV, CHIKV, YFV, ZIKV, and Malaria Pan/Pf (in preparation). |
Streptococcus suis (SS) |
|
HIV: Multi-patient test for up to 6 patients (in preparation). |
Porcine circovirus (PCV2b and 2d) |
|
Influenza A (sub-typing panel): In preparation. |
Swine influenza (H1N1 2009 and H1N2) |
|
PRRSV |
|
|
Influenza (H1,H3,H5, H7, H9) |
